IRLAB Therapeutics AB announced that the company's drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I. All documentation is currently being prepared in a Phase I clinical trial application to be submitted for regulatory approval. The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's and other neurological disorders with a once-daily oral administration. Apathy is a condition affecting over 20 million people in the US and Europe.

IRL757 has a unique pharmacology that reverses the state of disruption in cortical to sub-cortical nerve signaling, a proposed mechanism underlying apathy in neurological disorders.